International Targeted Oncology Drug Access Pathway国际特许肿瘤靶向与免疫联合治疗通道
国际特许肿瘤靶向与免疫联合治疗通道International Targeted Oncology Drug Access Pathway
Targeted therapy and immunotherapy are different treatment approaches. A biomarker may help identify a relevant medicine, but the same mutation or test result can have different meanings across tumour types and treatment settings.靶向治疗和免疫治疗是不同治疗方式。生物标志物可能帮助寻找相关药物，但相同突变或检测结果在不同肿瘤和治疗阶段可能有不同意义。
Hospital named in the catalogue目录所列医院
Clinical details below are in English. Ask the care team for help understanding the source documents.
What to clarify
How assessment and planning work评估与规划如何进行
Start with the complete pathology and molecular report, including the test method. The oncology team should identify the proposed medicine, evidence for that setting, prior-treatment requirements and monitoring. Access coordination follows that clinical decision.应先提供完整病理和分子报告及检测方法。肿瘤团队需明确药物、对应情境的证据、既往治疗要求和监测，临床决策后才进行可及性协调。
Before your consultation
Pathology, complete molecular report, prior medicines and current organ-function tests.病理、完整分子报告、既往药物及器官功能检验。
Send existing records for an initial discussion. Do not arrange new tests, change medication or book non-refundable travel solely from this page. The receiving team should state which additional information is actually needed.初步沟通可使用已有资料，不应仅凭本页安排新检查、改变用药或预订不可退款的行程。接诊团队应说明确实需要补充的资料。
Evidence and limitations
The risks depend on the particular medicine; an immunotherapy label does not imply fewer adverse effects. A quote should identify the product and dosing basis separately from testing and follow-up.风险取决于具体药物，免疫治疗标签不代表不良反应更少。报价应明确产品和计量依据，并与检测、随访费用区分。
Questions to ask
Can a molecular test establish eligibility for a medicine?分子检测是否直接证明可以使用某种药？
A biomarker can inform a discussion but does not by itself guarantee access or benefit. Confirm the medicine, cancer type, treatment line, test method and the treating clinician’s interpretation of the result.生物标志物可辅助讨论，但不保证可及性或获益。应确认药物、癌种、治疗线、检测方法及临床解读。
What should be included in my written treatment plan?书面诊疗方案应包括什么？
The treating team should identify the proposed intervention, alternatives, relevant uncertainty, clinical eligibility, anticipated visits, monitoring and arrangements if the plan changes after assessment. Ask who is responsible for follow-up after you return home.诊疗团队应明确拟议干预、替代方案、相关不确定性、适用条件、预计就诊次数、监测安排及评估后调整方案的处理方式，并说明回国后的随访负责人。
Price and quotation
Ask for an itemized provider quotation after the clinical team reviews your records. The scope may depend on the exact intervention, investigations, consumables, admission and monitoring. Confirm currency, validity period and what happens if the plan changes. Medical fees are paid directly to the provider; Uwell coordination is separate.临床团队审核资料后，可索取机构的分项报价。费用范围可能取决于具体干预、检查、耗材、住院和监测。应确认币种、有效期及方案调整后的计费方式。医疗费用直接向提供机构支付，优健云协调服务另行计费。
Reference catalogueSources and editorial scope
Prepared by Uwell’s content team from the cited documents; not a clinician-reviewed recommendation. Source review: 10 October 2026.
The clinical links provide background information. They do not verify the exact hospital programme, current authorization or an individualized treatment recommendation. The original provider must supply those details.临床链接提供背景知识，不代表已核实具体医院项目、当前授权或个体治疗建议，相关信息须由提供机构确认。